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Abstract
Background:  Executive functions, learning and attention are imperative facets of cognitive
performance, affected in many neuropsychiatric disorders. Recently, we have shown that
recombinant human erythropoietin improves cognitive functions in patients with chronic
schizophrenia, and that it leads in healthy mice to enhanced hippocampal long-term potentiation,
an electrophysiological correlate of learning and memory. To create an experimental basis for
further mechanistic insight into erythropoietin-modulated cognitive processes, we employed the
Five Choice Serial Reaction Time Task. This procedure allows the study of the effects of
erythropoietin on discrete processes of learning and attention in a sequential fashion.
Results: Male mice were treated for 3 weeks with erythropoietin (5,000 IU/kg) versus placebo
intraperitoneally every other day, beginning at postnatal day 28. After termination of treatment,
mice were started on the Five Choice Serial Reaction Time Task, with daily training and testing
extending to about 3 months.
Overall, a significantly higher proportion of erythropoietin-treated mice finished the task, that is,
reached the criteria of adequately reacting to a 1.0 sec flash light out of five arbitrarily appearing
choices. During acquisition of this capability, that is, over almost all sequential training phases,
learning readouts (magazine training, operant and discriminant learning, stability of performance)
were superior in erythropoietin-treated versus control mice.
Conclusion:  Early erythropoietin treatment leads to lasting improvement of cognitive
performance in healthy mice. This finding should be exploited in novel treatment strategies for
brain diseases.
Background
The haematopoietic growth factor erythropoietin (EPO)
has been in clinical use for over 20 years to treat patients
with anaemic conditions, ranging from renal failure to
cancer. Upon introduction of EPO to the clinic, it was
observed that cognitive performance of treated individu-
als also improved. This improvement was essentially
attributed to anaemia correction with subsequently
enhanced tissue oxygenation also in the brain [1]. Much
later, EPO and its receptor were found to be produced by
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and act on cells of the nervous system [2,3]. Many reports
on neuroprotective and neuroregenerative effects of EPO
in rodent models of neurological diseases followed [4]
(for review see [5,6]). Our recent human studies in schiz-
ophrenia and multiple sclerosis revealed profound EPO
effects on cognitive performance [7,8]. The separation of
haematopoietic and neuroprotective properties upon
slight modification of the EPO molecule ultimately
proved the haematopoiesis-independent effect of EPO on
the nervous system [6].
To investigate, in the absence of interfering disease varia-
bles, the physiological role of the brain EPO system
regarding cognition, we performed a series of studies in
healthy young mice where we found hippocampal mem-
ory, measured by classical fear conditioning, improved
after 3 weeks of EPO treatment. At the time of improved
memory, an increase in short-term and long-term poten-
tiation was documented in hippocampal slices [9]. Along
the same lines, application of a single high intravenous
dose of EPO in healthy human volunteers enhanced the
hippocampal response during memory retrieval measured
by functional magnetic resonance imaging one week later
[10]. It should, however, be also mentioned that preclini-
cal studies using disease models failed to show effects of
EPO treatment on cognition in their respective healthy
control groups (for example, [11,12]). This is most likely
explained by the application of tests (for example, T-
maze, 8-arm radial maze), well suited to measure pathol-
ogy but less sensitive for assessing subtle improvements in
cognitive performance in healthy individuals.
Since the development of new therapies, targeting cogni-
tive performance is of major interest for clinical neuro-
science, and EPO might here be a promising candidate;
thus the spectrum of cognitive functions potentially influ-
enced by EPO has to be better defined. For this purpose,
we employed the Five Choice Serial Reaction Time Task
(5CSRTT), originally developed for rats by Carli and col-
leagues [13] and adapted for mice by Humby and co-
workers [14]. The 5CSRTT has been used to analyse atten-
tion and executive functions in different rodent models of
neuropsychiatric diseases, including attention-deficit/
hyperactivity disorder [15], schizophrenia [16] and
impulsivity disorders [17] (for review, see [18]). With
5CSRTT, we systematically studied the effect of EPO on
different types of learning, memory and attention in
healthy young mice. We note that obtaining cognitive
results in healthy young individuals cannot automatically
be translated to disease situations or aged mice. Neverthe-
less, this approach is the simplest first step to providing a
foundation for mechanistic insight. We report here that
early EPO treatment indeed improves most of the sequen-
tial learning and memory components of a complex long-
term cognitive task, ultimately leading to better and more
stable cognitive achievements.
Results
Erythropoietin increases overall performance in 5CSRTT
First, we compared the overall performance of EPO, pla-
cebo, or no-inject groups in 5CSRTT. Kaplan-Meier analy-
sis revealed that the proportion of mice that finished
training in the 5CSRTT (that is, reached criteria of stably
responding to a 1.0-sec stimulus duration on three con-
secutive days) up to day 94 after cessation of treatment
was significantly higher in the EPO-treated group as com-
pared with placebo and no-inject groups (Log-Rank test, P
= 0.02). There were no differences between placebo and
no-inject groups (Figure 1). Taken as a group, EPO-treated
mice learn faster.
Erythropoietin accelerates associative, operant and 
discriminant learning in 5CSRTT
Since different types of learning determine performance
in the 5CSRTT, we asked whether the superiority of EPO-
treated mice is reflected in initial learning parameters.
Indeed, the number of head entries during habituation
and magazine training appeared higher throughout all
phases (M1–M4) in EPO-treated mice compared with the
Kaplan-Meier presentation of overall group performance in  mice Figure 1
Kaplan-Meier presentation of overall group perform-
ance in mice. Curves represent group performance (n = 
13–15 per group). They indicate the cumulative probability of 
members of each group not to finish the task (that is, not to 
reach performance criteria in the 1.0-sec stimulus duration 
phase). EPO-treated mice are superior, that is, have a lower 
probability not to finish the task as compared with no-inject 
and placebo groups. On day 59 after cessation of treatment, 
the first mouse reached criteria in the 1.0-sec phase. This 
mouse belonged to the EPO group. Day 94 is the time point 
on which > 60% of one experimental group (here the EPO 
group) had finished the task.
EPO
No-inject
Placebo
Days after cessation of treatment
P
r
o
b
a
b
i
l
i
t
y
 
n
o
t
 
t
o
 
f
i
n
i
s
h
 
t
h
e
 
t
a
s
k
p=0.02BMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37
Page 3 of 8
(page number not for citation purposes)
placebo group (Figure 2A). A significant difference
between groups in phases M1 and M4 of magazine train-
ing by Kruskal-Wallis test (P < 0.05 for each) could be
attributed to superior performance of the EPO versus pla-
cebo group following post hoc analysis (Dunn's multiple
comparison test, P < 0.01). During the operant learning
phase (S1), EPO-treated mice made more nose pokes
(ANOVA: F(1,41) = 8.81, P = 0.005) on days 2 and 3 (post
hoc P < 0.001 and P < 0.01, respectively) (Figure 2B).
Additionally, there was a significant group effect in the
discriminant learning phase (S2), with EPO-treated mice
demonstrating higher choice accuracy (ANOVA: F(1,41) =
5.35, P = 0.026) (Figure 2C).
We wondered whether the improvement in operant and
discriminant learning parameters would continue in face
of more complex conditions and thus enhanced cognitive
challenge during the 5CSRTT training. In fact, the 5CSRTT
procedure is much more complex than the preceding
shaping phases and consists of more parallel stimuli in
addition to stimulus duration (for example, number of
stimulus lights, more restricted time-out period). We ana-
lysed accuracy in the consecutive stimulus duration
phases: 16 sec, 8 sec and 4 sec. The percentage of correct
responses over the first 3 days of each phase served as rea-
dout of initial learning capabilities in the 5CSRTT training
(Figure 2D, E and 2F). EPO-treated mice performed better
in 16-sec and 8-sec phases (ANOVA F(1,41) = 7.21; P = 0.01
and F(1,39) = 4.87; P = 0.03, respectively, Figure 2D and
2E), but no longer in the following ones, from 4 sec (Fig-
ure 2F) to 2 sec, 1.8 sec, 1.4 sec, 1.2 sec and 1.0 sec (data
not shown). Overall accuracy increased over consecutive
phases until reaching a plateau at 4 sec for both groups,
which then stayed essentially stable over the following
Analysis of distinct sequential learning phases Figure 2
Analysis of distinct sequential learning phases. (A) Number of head entries as indicators of associative learning in maga-
zine training (M1–4) show an overall significant effect of EPO treatment compared with placebo. (B) Number of nose pokes in 
the operant learning phase (S1) as well as (C) percentage of correct nose pokes in the discriminant learning phase (S2) were 
higher in the EPO-treated compared with the control group (placebo plus no-inject). (D, E) Initial cognitive performance in 
the 5CSRTT was better upon EPO treatment in the 16-sec and 8-sec stimulus duration phases, but no longer in the 4-sec 
phase (F); n = 14–28 per group; data presented as mean ± S.E.M.; all significance values refer to post hoc tests which were only 
significant if ANOVA was also significant; in (E), only ANOVA was significant (P = 0.03).
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shorter-duration phases (data not shown). There was no
consistent difference in accuracy (nor amount of omis-
sions) during the attentional challenge phase of 0.8 sec
(F(1,18) = 0.49, P = 0.5 and F(1,18) = 1.45, P = 0.24, respec-
tively).
Erythropoietin improves task adaptation and stabilizes 
performance in 5CSRTT
We next analysed the number of training days required to
reach performance criteria in 5CSRTT for each stimulus
duration, that is, acquisition days (Figure 3A). There was
a significant effect of stimulus duration on the number of
training days needed, independent of treatment (F(7,126) =
8.24, P < 0.0001). Starting immediately from 2 sec, mice
required more days to reach criteria compared with previ-
ous phases. To further address the phenomenon of an
abrupt increase of training days in the 2-sec phase (inde-
pendently of treatment), we analysed omissions more
closely. In fact, omissions in all training phases from 16
sec to 1 sec were comparable between the two experimen-
tal groups, and rates were low up to the switch from the 4-
sec to the 2-sec phase (for illustration, data of the respec-
tive first training day of each stimulus duration are given
as an example: range of omissions on day 1 of 16 sec: 6.55
± 4.28 EPO versus 5.83 ± 4.17 control; on day 1 of 8 sec:
9.45 ± 13.09 EPO versus 8.93 ± 8.99 control; on day 1 of
4 sec: 16.90 ± 9.94 EPO versus 16.90 ± 9.81 control; on
day 1 of 2 sec: 29.78 ± 12.86 EPO versus 35.89 ± 10.27
control; on day 1 of 1.8 sec 22.11 ± 7.46 EPO versus 21.96
± 8.75 control; on day 1 of 1.4 sec: 27.00 ± 7.58 EPO ver-
sus 28.93 ± 11.12 control; on day 1 of 1.2 sec: 24.67 ±
8.21 EPO versus 24.1 ± 8.77 control; on day 1 of 1.0 sec:
24.7 ± 5.72 EPO versus 29.06 ± 10.29 control). It turned
out that from the 4-sec phase to the 2-sec phase, omis-
sions promptly doubled and stayed at a high level up to
the end of 5CSRTT training (1 sec), independent of treat-
ment group. This may explain the prominent increase in
training day requirement starting from 2 sec.
We next averaged omitted trials in each of the six 10-trial
blocks over the first 10 days of this 2-sec phase (Figure
3B). There was no significant overall effect of treatment;
however, there was a significant interaction between trial
block and treatment (F(5,130) = 2.37, P = 0.04). Post hoc
analysis revealed that EPO-treated mice had significantly
fewer omissions in the first trial block compared with con-
trols (P < 0.05), pointing to a faster adaptation to the task.
As fluctuations in performance may increase the number
of days needed for reaching performance criteria, we ana-
lysed the magnitude of fluctuation ('relapsing back from
already achieved criteria') in the 2-sec phase. Here, the
control group had significantly more relapses compared
with the EPO group, pointing to more stable performance
upon EPO (Chi2 test, P = 0.04) (Figure 3C). To further
explore the effect of EPO on stability of performance, we
analysed total omissions after reaching criteria (1.0 sec)
over additional 4 days. EPO-treated mice were superior (P
= 0.04) as compared with the control group (Figure 3D).
Erythropoietin does not affect locomotor activity in 
5CSRTT
To clarify whether increased locomotion has contributed
to the superior performance of EPO-treated mice in
Analysis of selected readouts of cognitive performance in high-performer mice Figure 3
Analysis of selected readouts of cognitive performance in high-performer mice. (A) Number of acquisition days 
required for reaching performance criteria at each stimulus duration phase shows no group differences but a sharp increase in 
the transition from 4 sec to 2 sec. (B) The EPO-treated group showed faster task adaptation: The proportion of omissions in 
the first of six 10-trial blocks collapsed across the first 10 days of the 2-sec phase was significantly lower. Post hoc test. (C) The 
EPO-treated group showed higher stability of performance: the proportion of mice that relapsed from already reached per-
formance criteria in the 2-sec stimulus duration phase was smaller. Chi2 test. (D) EPO improves performance stability even in 
the 1-sec phase: Proportion of total omissions over 4 days after reaching performance criteria was significantly lower in the 
EPO group. Mann-Whitney test. N = 7–28; data presented as mean ± S.E.M.
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phases with 16-sec and 8-sec stimulus duration, we ana-
lysed the average of reward latency (that is, the time
between responding correctly and collecting reward) as
well as the 'latency correct' (that is, the time between stim-
ulus presentation and responding correctly) in the corre-
sponding phases. There were no differences between
groups in either reward latency or in 'latency correct' in
any phase of the 5CSRTT training (data not shown).
Discussion
In the present study, a 3-week high-dose EPO treatment of
healthy young mice increased the probability of these ani-
mals finishing training in the 5CSRTT. While there were
no differences in the number of total days needed to ter-
minate the task among ultimately successful individual
mice, regardless of group assignment, the proportion per
group was different, with more successful mice in the
EPO-treated cohort. EPO-treated mice showed superior
performance in associative, operant and discriminant
learning as well as in initial 5CSRTT training phases.
Moreover, EPO-treated mice demonstrated better task
adaptation and higher performance stability. In contrast,
with the number of mice remaining in the task, there were
no clear effects with this particular EPO treatment sched-
ule (terminated more than 3 months before) on atten-
tional performance, as defined by response to the 0.8-sec
stimulus duration.
To gain an overall impression of the progress in cognitive
training of our mouse groups, we employed the survival
analysis of Kaplan-Meier. This methodological approach
was crucial for our purposes as it describes, over a long
testing period, the development of group performance in
a higher cognitive task, the 5CSRTT. By applying standard
statistical methods only, the clear superiority of the EPO
group would not have been detectable. In fact, the Kaplan-
Meier results inspired us to dissect out potential learning
processes contributing to the superior group performance
of EPO-treated mice. The success of this statistical
approach would suggest the usefulness of this method for
future group analysis in the 5CSRTT.
While clear benefits of EPO treatment could easily be
demonstrated throughout all initial learning phases
including the 5CSRTT training up to 8-sec stimulus dura-
tion, we did not find differences in accuracy in phases
with stimulus durations of 4 sec and below. This might be
due to a ceiling effect, as both groups had reached almost
maximal performance at this stage. Nevertheless, also in
these more progressed phases, EPO superiority was visible
when analysing more subtle readouts of cognitive per-
formance, for example, stability and task adaptation.
A particularly difficult 5CSRTT training step for mice is the
switching from the 4-sec to the 2-sec stimulus duration
phase. In this challenging phase, EPO-treated mice had
consistently lower omission rates when entering the task,
indicating immediate task adaptation. This improvement
just failed to translate into significant differences in acqui-
sition days. Interestingly, a previous study on galanin
transgenic mice, a model for impaired learning capacity,
reported for this critical 2-sec phase more than doubling
of required training days compared with controls, due to
more omissions [19]. In contrast to the improved task
adaptation shown in the present study, reflected by less
omissions in the first trial block, galanin transgenic mice
exhibited more omissions in the last two trial blocks,
pointing to deficiency of sustained attention [19]. In con-
trast to all other studies employing 5CSRTT, we have addi-
tionally analysed parameters representing stability of
Experimental design Figure 4
Experimental design. Following 3 weeks of EPO (5,000 IU/kg body weight intraperitoneal) versus placebo (diluent control) 
treatment or handling only (no-inject group), 7-week-old mice go through habituation/magazine training (M1–M4) and shaping 
phases (S1–S2) before starting training in the 5CSRTT. Here they move from 16 sec to the respective next phase with lower 
stimulus duration (8 sec and so on) upon reaching fixed criteria. Having reached criteria in the 1.0-sec phase, their attention is 
challenged by further shortening stimulus duration (0.8 sec).
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performance. The analysis of relapse frequency (that is,
dropping down from a once-acquired performance level)
in the challenging 2-sec stimulus duration phase with its
increasing attentional challenge again revealed a more
consistent performance by the EPO group.
An important limitation of the current study (and of
5CSRTT in general) has to be addressed: the strong selec-
tion bias of mice with higher cognitive abilities means
that mice that do not learn crucial steps of the task are
excluded from further testing (which is frequently not
mentioned in respective publications). This gradual
decrease of numbers in advanced training phases renders
statistical analysis increasingly difficult. For instance, in
the current study, there would not have been enough mice
in the placebo and the no-inject group for separate analy-
sis in the attentional phase with stimulus duration of 0.8
sec, despite starting out with 15 mice per group. A total of
45 mice to be run simultaneously in this task already
reaches the limits of a generous set-up of five chambers
and more than a full working day of the investigator. Since
performance of placebo and no-inject groups did not dif-
fer much in the early phases, pooling of both groups to
obtain a 'control cohort' was possible.
Conclusion
The findings of the present study, that is, improved
sequential learning and memory components of a com-
plex long-term cognitive task upon EPO treatment, will
provide the basis for further work targeting molecular fac-
ets of these critical phases. Such studies will include quan-
titative and qualitative evaluation of neurogenesis and
synapse formation in respective brain regions, for exam-
ple, cingulate cortex and hippocampus. In the latter, we
recently detected increased long-term potentiation after
EPO treatment [9]. In addition, future work will have to
assess whether the effects of EPO obtained here are
restricted to the use of very young and healthy animals, or
would be similarly strong in older mice and/or disease
conditions. Further untangling of molecular mechanisms
of EPO action on higher cognitive functions may then
ultimately open new avenues for prevention strategies and
therapeutic interventions in neuropsychiatric diseases.
Methods
Animals
Forty-five male C57BL/6NCrl mice (Charles River,
Sulzfeld, Germany), 3 weeks old upon arrival, were
housed in groups of five in standard plastic cages, with
food and water ad libitum. The temperature in the colony
room was maintained at 20–22°C, the light-dark cycle at
12 h (light on at 0400 hrs). After 7 days of acclimatising
to the new environment, injections were started at the age
of 28 days and were always performed in the first half of
the light phase. Behavioural experiments were conducted
by an investigator, blinded to treatment condition, during
the second half of the light phase (between 1000 hrs and
1500 hrs). All experiments were approved by the local
Animal Care and Use Committee in accordance with the
German Animal Protection Law.
Injection protocol
Mice were randomly assigned to one of three groups: EPO,
placebo or 'no-inject' (to uncover potential effects of
repeated injection stress), each consisting of 15 mice.
Mice were intraperitoneally injected every other day for 21
days (11 injections in total) either with EPO (5,000 IU/kg,
Epoetin-alpha, Janssen-Cilag, Neuss, Germany) or with
placebo (diluent buffer) in a volume of 0.01 ml/g body
weight. Mice from the no-inject group were just weighed
every other day (in order to keep handling similar to the
injected mice) with no additional manipulations. Train-
ing started 1 day after cessation of injections.
5CSRTT apparatus
Mice were trained in an operant chamber (height 18 cm,
width 15.5 cm, depth 20 cm, Med Associates Inc, St.
Albans, USA), enclosed in a sound-attenuating box and
connected to a Fujitsu Siemens PC. One wall of the oper-
ant chamber had a curved shape and carried an array of
five stimulus holes. The stimulus holes were 1.2 cm in
diameter and contained an LED stimulus light (depth 1
cm) in the rear. Infrared photocell pairs were located at 4
mm from the entrance of the stimulus holes and detected
nose pokes of mice into the holes. The wall opposite to
the stimulus holes contained a magazine cup, also with a
photocell detector of head entries, in which liquid reward
(4% sucrose solution) was delivered always simultane-
ously with illumination of the magazine. The house light
was located 32 cm above the magazine.
Habituation and magazine training
Two days before starting training, mice were habituated to
the liquid reward of 4% sucrose solution in their home
cages overnight. The day before starting magazine train-
ing, sucrose bottles were removed and mice were water-
deprived. Water deprivation was applied during the whole
experimental period. Immediately after finishing the daily
test sessions, mice were given water in individual cages for
20 min. Magazine training consisted of four consecutive
phases (M1–M4), one phase per day, each lasting for 15
min, with all stimulus holes closed. In the first phase
(M1), liquid reward was delivered (10 μl) upon initiation
of the training session. In the second phase of magazine
training (M2), the number of potential rewards was
increased, with a fixed interval of 118 sec between reward
presentations. A head entry into the magazine was
required to collect the reward. In the third phase (M3), the
fixed interval was replaced by a head entry-dependent
interval of 100 sec to obtain reward. In the last phaseBMC Biology 2009, 7:37 http://www.biomedcentral.com/1741-7007/7/37
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(M4), this interval was further reduced to 50 sec, ideally
yielding a consistently increasing number of head entries.
Head entries into the magazine together with reward con-
sumption were taken as indicators for associating the
magazine with reward delivery (see experimental design
Figure 4).
Shaping phases (operant and discriminant learning)
During shaping, mice were trained to perform a nose poke
into an illuminated stimulus hole in order to obtain
reward. The shaping procedure consisted of two phases
(each extending over several days, dependent on individ-
ual performance, and with a daily session duration of 30
min) where mice were taught to associate nose poking
into an illuminated hole with reward (phase S1), and then
trained to discriminate between those nose pokes that
lead to reward (illuminated holes) and those that do not
(unlit holes) (phase S2) (Figure 4). Throughout shaping
all stimulus holes were open. During S1, all stimulus
lights were on. Any nose poke in a stimulus hole was
rewarded. The inter-trial interval (time from pick-up of
reward to next stimulus hole illumination) was set to 8
sec. During S2, presentation of lit and unlit holes was con-
ducted in a pseudorandom manner. Mice were only
rewarded upon nose poking into a lit stimulus hole. Per-
forming a nose poke in an unlit hole led to switch-off of
the house light for 5 sec. Mice in S1 were moved to the
next training phase once they had reached 35–40 nose
pokes each on three consecutive days. S2 was terminated
when mice had arrived at a stable performance of ≥ 70%
correct responses. Starting from analysis of shaping
phases, placebo and no-inject groups were pooled, since
they no longer differed in any of the high-performing
tasks beyond habituation.
5CSRTT training
The training session started with illumination of maga-
zine light and presentation of 4% sucrose solution. Head
entry started the trial. At 8 sec after head entry, light (ini-
tially set to 16 sec) was randomly presented in one of the
five stimulus holes. A correct response, that is, nose pok-
ing into the lit hole, led to reward (6 μl) and next trial start
after 8 sec. Nose poking in an unlit stimulus hole, that is,
an incorrect response, led to extinguishing the house light
for 5 sec (time-out) and no reward. Further nose pokes
during time-out extended that period for additional 5 sec
each. If a mouse did not respond by nose poking into any
of the holes during stimulus presentation, an omission
was counted. As a consequence, no reward was presented.
Also omissions provoked time-out. A training session was
terminated after 30 min or upon performing 60 trials,
whichever came first. Mice were trained in the phase with
16-sec stimulus duration until they reached clearly
defined performance criteria (≥ 75% accuracy (correct
responses/correct + incorrect responses * 100), ≤ 20%
omissions and at least 50 trials performed over three con-
secutive days). Eight such phases followed with gradually
declining stimulus duration up to 1.0 sec (16, 8, 4, 2, 1.8,
1.4, 1.2, and 1.0 sec).
In the first phases, mice had time to respond as long as the
stimulus light was on. For phases with stimulus duration
below 5 sec, the response time (so-called limited hold)
was added up to 5 sec. Having 'finished the task' meant
having reached the above performance criteria for the 1.0
sec phase. Training sessions were performed every day,
including weekends. As soon as > 60% of the mice in one
of the three experimental groups had finished the task by
reaching performance criteria in the 1.0 sec phase, regular
5CSRTT training was stopped for all groups (day 94; Fig-
ure 1) and only high performers of all groups were carried
on with attention testing, that is, stimulus duration below
1.0 sec (0.8 sec). This resulted in EPO n = 10 versus con-
trol n = 10 (placebo n = 4 plus no-inject n = 6).
Overview on parameters of task acquisition
The following parameters were employed: (1) proportion
of mice that finished the task in all experimental groups;
(2) number of days until reaching performance criteria in
all phases (acquisition days); (3) proportion of omis-
sions, that is, number of omitted per total number of per-
formed trials within one training session; (4) number of
head entries during a magazine training session; (5)
number of nose pokes during an operant learning session;
(6) accuracy, that is, percentage of correct responses calcu-
lated as number of correct responses/correct + incorrect
responses*100; (7) sustained attention, that is, atten-
tional performance, expressed as omissions as a function
of time in session, evaluated over the first 10 days in the
2-sec phase (the most challenging training step). Data are
expressed in 10-trial blocks collapsed across all 10 days;
(8) newly introduced parameter: Stability of performance/
relapses, that is, the ability to maintain a high performance
with respect to omissions and accuracy for three consecu-
tive days. Mice that reached the above mentioned criteria
without keeping them for the required 3 days were consid-
ered relapsing. An additional measure of performance sta-
bility in high performers were omissions in the 1.0-sec
stimulus duration phase, as determined for 4 days after
reaching criteria.
Statistical analysis
Statistical analysis was performed using the statistical pro-
grams SPSS for windows, release 16 (SPSS Inc., Chicago,
USA) and GraphPad Prism version 4.00 for Windows,
(GraphPad Software, San Diego, USA). We applied two-
way ANOVA repeated measures, Kruskal-Wallis test, chi2-
test and Mann-Whitney test where indicated. Bonferroni
and Dunn's multiple comparison tests were used for post
hoc analysis. Threshold for significance was P < 0.05. Sur-Publish with BioMed Central    and   every 
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vival analysis/Kaplan-Meier curves [20] were introduced
to demonstrate the proportion of mice per group finish-
ing the 5CSRTT training up to the 1.0-sec stimulus dura-
tion (task goal). Mice that did not reach the goal until day
94 were censored.
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